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The immunological relationship between reverse transcriptases purified from human T-cell lymphotropic 
viruses (HTLV-I, HTLV-II, HTLV-III) was defined using monoclonal antibodies specific for HTLV-III re- 
verse transcriptase, secreted by a mouse/mouse hybridoma clone (4F8) developed in our laboratory. The 
viral proteins from HTLV-I and HTLV-II do not bear any cross-reactive pitope to antibodies secreted by 
this clone. These antibodies specifically cross-react with HTLV-III reverse transcriptase. The antibodies 
failed to neutralize the catalytic activity of reverse transcriptase; however, after immunoprecipitation with 
a magnetic conjugate of goat anti-mouse IgG, the residual activity was completely inhibited. This shows 
that the antibodies are not directed towards the catalytic active center of the enzyme. Using an immunoblot- 
ting technique (Western blotting), we have found two cross-reactive proteins with HTLV-III lysate with 
molecular masses of 53 and 66 kDa. This suggests that HTLV-III possesses two reverse transcriptase activi- 
ties with a common determinant recognized by the same epitope. 
Monoclonal antibody Reverse transcriptase Human lymphotropic virus AIDS 
1. INTRODUCTION 
Human T-cell lymphotropic retroviruses 
(HTLV) constitute a well characterized group of 
retroviruses, with tropism for OKT4+ T-helper 
cells. Three subgroups have been identified. 
HTLV-I, isolated in 1980 [l], is the etiological 
agent of adult T-cell leukemia; HTLV-II, first 
isolated from a patient with hairy cell eukemia [2], 
has not yet been linked to any human disease. 
More recently, a third member of this family, 
HTLV-III [3,4], has been shown to be the 
etiological agent of the acquired immune deficien- 
cy syndrome (AIDS). HTLV-III is similar to the 
The subtype classification of the AIDS- 
associated virus as HTLV-III was implicated by 
the initial observations of Essex et al. [6,7] who 
reported antibodies to HTLV-I antigens in patients 
with AIDS, followed by a series of immunological 
data and homologies in nucleic acid sequences. 
Schupbach et al. [8] and Sarngadharan et al. [9] 
have reported that some of the antigens of HTLV-I 
and HTLV-III bear cross-reactive pitopes. The se- 
quence studies using cloned HTLV-III and HTLV- 
I genomes have revealed some sequence 
homologies, especially in the gag/p01 region, be- 
tween both the viruses [lo, 111. 
* To whom correspondence should be addressed To study the cross-reactivity between antigens of 
lymphadenopathy-associated virus (LAV), previ- 
ously described by Barre-Sinoussi et al. [5]. 
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HTLV-III and other related viruses, we have 
recently generated hybridoma (mouse/mouse) 
clones which secrete monoclonal antibodies to ~24, 
~31, gp41, gp120 and reverse transcriptase. Here, 
we will describe the serological analysis of reverse 
transcriptases purified from HTLV-I, HTLV-II 
and HTLV-III, using monoclonal antibodies to 
HTLV-III reverse transcriptase; the hybridoma 
clone used carries the designation 4F8. 
2. EXPERIMENTAL 
Human T-cell lymphotropic viruses I, II and III 
were obtained from Dr R.C. Gallo and Dr Prem 
Sarin, National Cancer Institute, Bethesda, MD, 
USA. 
2.1. Preparation of monoclonal antibodies 
BALB/c mice were immunized with successive 
intraperitoneal inoculations of detergent lysates 
(1% Triton X-100) of density-gradient purified 
HTLV-III produced in H9 cells. First inoculation 
was done with 15Opg viral protein emulsified in 
complete Freund’s adjuvant, followed by 3 
boosters given 2 weeks apart using 1OOpg of the 
viral antigen in incomplete Freund’s adjuvant. The 
last booster was given with a purified preparation 
of reverse transcriptase from HTLV-III (5Opg 
protein) in incomplete Freund’s adjuvant. 84 h 
after the 5th inoculation, splenic lymphocytes (1 x 
lo8 cells) were mixed with NS-1 mouse-myeloma 
cells (4 x 10’ cells) and centrifuged (1000 x g, 
7 min). The fusion procedure, cell culturing and 
cloning of hybridomas were similar to the pro- 
cedures described in [ 121. 
Supernatant fluids from the hybridoma cultures 
were screened for antibodies to HTLV-III proteins 
by the enzyme-linked immunosorbent assay 
(ELISA) in which we used disrupted HTLV-III as 
antigen. Hybridoma cultures which reacted 
positive in this assay were further analyzed by 
Western blotting and by ELISA using purified 
reverse transcriptase as one of the antigens. One 
hybridoma clone, designated 4F8, was found to 
secrete antibodies reacting only with the purified 
reverse transcriptase. 
For preparing ascites fluid containing 
monoclonal antibodies BALB/c mice were primed 
by injecting 0.5 ml pristane (2,6,10,14_tetra- 
methylpentadecane) intraperitoneally. lo-14 days 
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later 5 x 106-1 x 10’ exponentially growing hy- 
bridoma cells were transplanted by the same route. 
After 2-3 weeks, 2-6 ml ascites were obtained. 
2.2. Purification of reverse transcriptases 
Reverse transcriptases from HTLV-I, HTLV-II 
and HTLV-III were purified as in [ 13,141. 
However, we discovered that HTLV-III reverse 
transcriptase contains a glycoprotein as contami- 
nant which cannot be removed by the usual 
purification procedures [ 15,161. For this reason, 
HTLV-III reverse transcriptase was additionally 
purified by affinity chromatography on lectin- 
Sepharose 4B (Pharmacia, Freiburg) column, us- 
ing a-methylmannoside as eluent to remove the 
glycoprotein. 
2.3. Immunoblotting (Western blotting) 
Lysates from HTLV-I, HTLV-II and HTLV-III 
were fractionated by SDS-polyacrylamide slab gel 
(PAGE) electrophoresis [14]. The proteins were 
transferred to nitrocellulose sheets using an elec- 
troblotting device ‘(LKB Transphor, unit 2005) 
overnight at 35 V. The nitrocellulose sheets were 
incubated overnight at 4°C in phosphate-buffered 
saline (PBS) containing 3% bovine serum albumin 
(BSA). The sheets were cut into strips and kept at 
-80°C until used. 
Each strip was incubated at 37°C for 2 h in PBS 
containing 2.5% BSA, 2.5% normal goat serum 
and 0.05% Tween 20. The strip was washed with 
PBS-Tween buffer and incubated with hybridoma 
medium (1: 100) for 30 min at 37°C. The strip was 
washed again and incubated with biotinylated 
goat anti-mouse IgG (1: 1000) for 30 min at 37°C. 
After washing in PBS-Tween buffer, the strip was 
reincubated in PBS containing horseradish 
peroxidase-avidin D conjugate for 30 min at 37°C. 
After final washing, the strip was incubated at 
room temperature in PBS containing 4-chloro_Lu- 
naphthol (0.75 mg/ml), methanol (25%) and 2% 
solution of hydrogen peroxide (60,&5 ml). The 
strip was washed twice and finally air-dried. 
2.4. Assay of reverse transcriptase activity 
Reverse transcriptase activity was measured by 
adding 20 ,ul of the enzyme fraction to a volume of 
30 ~1, which gave a final concentration of 50 mM 
Tris-HCl buffer (pH 8.0), 50 mM KCl, 15 mM 
MgC12, 1 mM dithiothreitol, 20/rM each of the 
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complementary dNTP, or tritium-labeled dGTP 
and 1.25 pg template primer (rC),- (dG)lz. The 
reaction mixtures were incubated for 30 min at 
37°C. The reaction was terminated by the addition 
of 0.36 mg BSA and 3 ml trichloroacetic acid 
(10070, w/v) containing 20 mM Na pyrophosphate. 
Acid-precipitable material was collected on What- 
man glass-fibre discs (GF/C), washed and counted 
in a scintillation spectrometer. Each assay was car- 
ried out in triplicate. 
3. RESULTS AND DISCUSSION 
Biochemical characterization of the purified 
reverse transcriptase from HTLV-III has been 
reported from this laboratory [13,14]. In these 
studies, the enzyme was purified from disrupted 
virions by column chromatography on DEAE- 
cellulose columns (DE 23 and DE 52, Serva, 
Heidelberg), followed by a final purification on 
the phosphocellulose column. The step-wise isola- 
tion yielded an approx. 2000-fold purification of 
reverse transcriptase starting from the virus lysate 
[ 13,141. The MI of this enzyme which eluted as a 
single peak of activity from the phosphocellulose 
column was estimated to be 98000. Using this 
preparation in this study to characterize the 
hybridoma clones, we discovered a cross-reactivity 
for this antigen by hybridoma clones secreting an- 
tibodies to reverse transcriptase and gp41. This in- 
dicated to us that the reverse transcriptase used in 
our study was contaminated by a glycoprotein, 
probably gp41. Further purification of the 
phosphocellulose nzyme on a 1ectinSepharose 4B 
column removed the glycoprotein, and we were 
able to obtain a reverse transcriptase which showed 
no cross-reactivity with other hybridoma fluids. 
The hybridoma clone secreting monoclonal an- 
tibodies which reacted specifically to HTLV-III 
reverse transcriptase was designated 4F8, and used 
in our serological experiments. 
The supernatant fluid obtained from the clone 
4F8 was screened by ELISA using disrupted 
HTLV-III as antigen. Wells of a 96-well plastic 
tray were coated overnight with lysates of density- 
banded HTLV-I, HTLV-II and HTLV-III contain- 
ing different amounts of antigen (table 1). The re- 
maining protein-binding sites were saturated with 
1% BSA in PBS. 50 pl of the hybridoma superna- 
tant was then added to each well and incubated for 
1 h at 37°C. The immuno-reactivity was measured 
by adding affinity purified goat anti-mouse 
IgG + M conjugated with ,&galactosidase, using p- 
nitrophenyl-P-D-galactopyranoside as substrate. 
The activities were measured at 405 nm in an 
ELISA reader. 
The results shown in table 1 demonstrate that 
viral proteins from HTLV-I and HTLV-II do not 
Table 1 






IT.405 X lo3 at various virus (protein) concentrations 
O(PBS/BSA) 15 30 60 125 250 500 loo0 
(ng/well) 
57 63 63 55 57 55 67 53 
64 69 64 51 63 77 60 50 
50 60 61 54 75 96 198 288 
Supernatant fluid obtained from clone 4F8 was screened by ELISA using 
disrupted HTLV-III as antigen. Wells of a 96-well plastic tray were coated 
overnight with HTLV-I, HTLV-II and HTLV-III lysates containing different 
amounts of antigen. After saturation of the remaining protein-binding sites with 
1% BSA, 50~1 of culture supernatant from 4F8 was added to each well. The 
cross-reactivity was measured byadding anti-mouse IgG + M conjugated with 
&galactosidase, using p-nitrophenyl-B-D-galactopyranoside a  substrate. The 
activities were measured in an ELISA reader at 405 nm 
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bear any cross-reactive epitope to antibodies 
secreted by the clone 4F8. As a control in these ex- 
periments, BSA was used. On the other hand, a 
con~ntration-dependent cross-reactivity is ex- 
hibited by the viral antigens from HTLV-III 
against antibodies secreted by 4F8 clone. 
Following the procedure described above, wells 
of swell plastic trays were coated overnight with 
reverse transcriptases purified from HTLV-I, 
HTLV-II and HTLV-III. To document the 
specificity of 4F8 clone for reverse transcriptase, 
another hybridoma clone secreting monoclonal an- 
tibodies against the gp120 antigen of HTLV-III, 
designated 1A6, was included in this experiment. 
As follows from table 2, no cross-reaction between 
reverse transcriptases of HTLV-I and HTLV-II 
was observed towards antibodies to HTLV-III 
reverse transcriptase (clone 4F8). In the same ex- 
periment, the antibodies secreted by the clone lA6 
show no cross-r~ctivity towards the HTLV-III 
reverse transcriptase. 
The specificity of antibodies secreted by the 
clone 4F8 for HTLV-III reverse transcriptase was 
further documented by immunoblotting. The elec- 
trophoretic separation of lysates from HTLV-I 
(lane l), HTLV-II (lane 2) and HTLV-III (lane 3) 
are shown in fig. 1A; lane 4 shows the separation of 
affi~ty-puri~ed Mr markers (phosphoryl~e b, 
94oOp; BSA, 67000; ovalbumin, 43ooO; carbonic 
anhydrase, 30000; soybean trypsin inhibitor, 
20100 and cu-lactalbumin, 14400). Fig.lB depicts 
the immunoblots of HTLV-I (lane l), HTLV-II 
(lane 2) and HTLV-III (lane 3), developed against 
antibodies secreted by the clone 4F8. There is no 
cross-reacting band seen on HTLV-I and HTLV-II 
strips. The strip with HTLV-III shows two promi- 
nent bands in the region of Mr 53000 and 66000. 
To separate the two reactivities, the clone 4F8 was 
subjected to repeated cycling. Even after the 4th 
cycling of 4F8 clone, the two reactivities could not 
be separated. This indicates that both the reactive 
antigens, 53 and 66 kDa proteins, have a common 
determinant recognized by the same epitope. 
To elucidate the biochemical nature of 
4F8-antibody interaction to HTLV-III reverse 
transcriptase, we have measured the catalytic ac- 
tivity of reverse transcriptase in the presence of an- 
tibodies. The data in table 3 show that antibodies 
secreted by the clone are unable to neutralize the 
enzymatic activity. Measurement of residual activi- 
Table 2 
Serological relationship between reverse transcriptases from human T- 
Iymphotropic viruses defined by monocional antibodies to HTLV-III-RT 
Experiment E.+a5 x lo3 at various RT concentrations (protein) 
O(PBS/BSA) 15 30 60 125 250 500 loo0 
(ng/well) 
HTLV-I 
K8) 51 56 44 48 47 68 48 39 
(lA6) 45 44 41 45 56 56 53 39 
HTLV-II 
E8) 45 45 56 46 54 61 51 39 
(IA6) 49 42 42 48 53 55 50 42 
HTLV-III 
;8) 55 44 49 70 82 154 231 287 
(lA6) 44 50 56 52 50 53 55 42 
Following the procedure described in the text and table 1, wells were coated 
overnight with various amounts of reverse transcriptases purified from HTLV- 
I, HTLV-II and HTLV-III. The clone lA6, serving as negative control, secretes 
antibodies against glycoprotein gp120 
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Fig. 1. (A) SDS-polyacrylamide gel electrophoresis of 
virus lysates. lOO$ virus suspension containing 4~1 
Tris-HCl (pH 6.8), 20 ~1 SDS and DTT (1’70) was 
incubated in a boiling water bath for 5 min. To this were 
added 80~1 glycerine and 10~1 bromophenyl blue 
(10%); 15 ~1 of this suspension was used per slab. Other 
experimental details have been described [ 141. Lanes: 1, 
HTLV-I; 2, HTLV-II; 3, HTLV-III; 4, protein markers: 
phosphorylase b (94 kDa), bovine serum albumin 
(67 kDa), ovalbumin (43 kDa), carbonic anhydrase 
(30 kDa), soybean trypsin inhibitor (20.1 kDa), cy- 
lactalbumin (14.4 kDa). (B) Immunoblot transfer 
analysis of antigenic cross-reactivities of HTLV-I, 
HTLV-II and HTLV-III towards antibodies secreted by 
hybridoma 4F8. Lanes: 1, HTLV-1; 2, HTLV-II; 3, 
HTLV-III. Experimental details are described in section 
2. 
ty by immunoprecipitation of the antigen-antibody 
complex however, shows a concentration- 
dependent inhibition of the enzyme activity. These 
data indicate that the antibodies secreted by 4F8 
clone are not directed towards the active center of 
HTLV-III reverse transcriptase. 
Table 3 
Catalytic activity of HTLV-III reverse transcriptase in 
the presence of antibodies secreted by the hybridoma 
clone 4F8 
Antibody [3H]dGMP incorporation 
concentrationa (pmol/lO ~1) 
Neutralizingb Residual’ 
activity activity 
Controld 1 lo(lOO)c 12qlOO) 
1:2000 ND 51.6(43) 
1:200 99.3 (90.2) 22.8(18.9) 
1:20 92.28(83.9) ND 
a Ascites prepared from clone 4F8 (see section 2) was 
used as the source of antibodies. The dilution factor 
depicts the concentration of antibodies in the ascites 
fluid 
b Neutralizing activity was measured by preincubating 
c 
20 ~1 of the enzyme with 20 ~1 of the properly diluted 
ascites fluid overnight. 10 pl of this was used to assay 
the enzyme activity 
10 pl of the enzyme was preincubated with 10 ~1 of the 
properly diluted ascites overnight at 4°C. To this was 
added 100 ~1 of magnetic conjugate of goat anti-mouse 
IgG (Biomag M4400, Sebak, Aidenbach, FRG), and 
the tubes were placed on a magnetic separation device 
(Sebak). After 1 h, 30~1 aliquots were pipetted from 
the supernatant and assayed for the residual enzyme 
activity. All estimations were done in triplicate 
Q In the control experiments, 1: 100 dilution of ascites 
from another clone which showed no cross-reactivity 
to reverse transcriptase was used. Other procedures 
were identical 
’ Figures in parentheses represent he percent of control 
value 
The biochemical and immunological data 
presented above suggest that there are two forms 
of reverse transcriptase activities having a common 
determinant for the antibodies secreted by clone 
4F8. The antibodies secreted by clone 4F8 are non- 
neutralizing, and are specific for HTLV-III reverse 
transcriptase. Thus, the reverse transcriptase of 
HTLV-III is serologically different from those 
from HTLV-I and HTLV-II. Immunoblotting 
shows two forms of reverse transcriptase of Mr 
53000 and 66000. There are two possible 
mechanisms to explain this heterogeneity of 
HTLV-III reverse transcriptase: one possibility is 
that the product of the pol gene is a polyprotein 
331 
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which is processed at different sites producing two 
forms of the molecule; the other is that the parent 
enzyme of Mr 66000 is processed by a protease 
associated to the HTLV-III genome. Experiments 
evidence is in favor of the second possibility. We 
have recently shown [14] that HTLV-III reverse 
transcriptase can be separated by isoelectric focus- 
ing into two peaks with isoelectric points of 5.75 
and 6.25. These differences are probably due to 
cleavage of roughly 100 amino acids from the car- 
boxy1 end by a specific protease. The characteriza- 
tion of two enzymes eparated by isoelectric focus- 
ing should help in answering these questions. 
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